In addition, several Phase II studies on the intratumoral administration of L19-IL2 plus L19-TNF in patients with metastatic melanoma (NCT02076633) or nonmelanoma skin cancer (NCT04362722; NCT05329792) are ongoing (199). This evidence concerns the gene IL2 and metastatic melanoma.